Grahame Mansell-Grace Business Development Manager. KEY ISSUES FOR COMMERCIALISING MEDTECH IDEAS 28 November 2013

Transcription

1 Grahame Mansell-Grace Business Development Manager KEY ISSUES FOR COMMERCIALISING MEDTECH IDEAS 28 November 2013

2 70 BILLION + * Horizon 2020 is now expected to receive 78.6bn in current prices over the next seven years and includes funding for nuclear research under the EURATOM. The final budget is an increase of nearly 30% in real terms compared with its predecessor, FP7.On this basis, the budget agreed for Horizon 2020 was 70.2bn. This baseline is adjusted for inflation (assumed to be 2% a year) over the lifetime of the programme to get to amounts in current prices. Current prices represent the real money that will be requested to the budget authority and finally distributed to beneficiaries through calls. *

3 What am I going to talk about? Benefits of Grant Funding Horizon 2020 Funding Key Points What is Horizon 2020? What s new in Horizon 2020? Three pillars of Horizon 2020 Horizon Simplification and Broader areas GHA GHB

4 Benefits of Grant Funding Funding to support the planned development of advanced technology Advance development of projects moving closer to market Collaboration with key players from across Europe Facilitating Investment in your organisation Reduce risk in some cases of using a companies monies Access to new markets/geographic areas Marketing and/or technology intelligence Visibility within the EC Shorten R & D Timescales Enable collaborations with organisations with complementary knowledge/technology

5 Horizon 2020 Funding Key Points Starts 1 January 2014 to end of 2020 Grants available for co-financing innovative R & D projects Advance development of projects moving closer to market Generally, grants require a consortium of a minimum of 3 independent organisations from 3 different EU Member States Consortium partners can come from industry or academia Introduction of Technology Readiness Levels (TRLs) Funding for Research and Technological Development activities is generally 100% lower TRLs 2-4 and 70% TRL 5-8 New SME Instrument which needs just 1 SME in the main Overall shorter timescale to grant receipt planned IP is retained by the project partners Grant is payable annually in advance

6 Technology Readiness Levels (TRLs) TRL 0 Idea TRL 1: Basic Research TRL 2 Technology formulation TRL 3 Applied Research TRL 4 Small Scale Prototype Development Unit (PDU) TRL 5 Large Scale Prototype Development Unit TRL 6 Prototype System TRL 7 Demonstration System TRL 8 First of the kind commercial System TRL 9 Full commercial application Unproven idea or concept where no peer reviewed analysis or testing has been performed The initial scientific research has been completed. The basic principles of the idea have been qualitatively postulated and observed. The process outlines have been identified. No experimental proof and detailed analysis are yet available The technology concept, its application and its implementation have been formulated. The development roadmap is outlined. Studies and small experiments provide a proof of concept for the technology concepts The first laboratory experiments have been completed. The concept and the processes have been proven at laboratory scale, table-top experiments. Potential of materials and up scaling issues have been identified The components of the technology have been identified. A PDU has been built a laboratory and controlled environment. Operations have provided data to identify potential up scaling and operational issues. Measurements validate analytical predictions of the separate elements of the technology. Simulation of the processes has been validated. Preliminary LCA and economy assessment models have been developed The technology has been qualified through testing in intended environment, simulated or actual. The new hardware is ready for first use. Process modelling (technical and economic) is refined. LCA and economy assessment models have been validated. Where it is relevant for further up scaling the following issues have been identified: Health & safety, environmental constraints, regulation, and resources availability The components and the process have been up scaled to prove the industrial potential and its integration within the energy system. Hardware has been modified and up scaled. Most of the issues identified earlier have been resolved. Full commercial scale system has been identified and modelled. LCA and economic assessments have been refined The technology has been proven to work and operate a pre-commercial scale. Final operational and manufacturing issues have been identified. Minor technology issues have been solved. LCA and economic assessments have been refined The technology has been proven to work at a commercial level through a full scale application. All operational and manufacturing issues have been solved The technology has been fully developed and is commercially available for any consumers

7 What is Horizon 2020 * Budgets agreed for over 70 billion euro research and innovation funding programme ( ) Part of proposals for next EU budget, complementing Structural Funds, education, etc. A core part of Europe 2020, Innovation Union & European Research Area: Responding to the economic crisis to invest in future jobs and growth Addressing peoples concerns about their livelihoods, safety and environment. Strengthening the EU s global position in research, innovation and technology All information is based on approximate and potential details from the European Commission and subject to change

8 What s new in Horizon 2020 A single programme bringing together three separate programmes/initiatives* Coupling research to innovation - from research to retail, all forms of innovation closer to market projects than FP7 Focus on societal challenges facing EU society, e.g health, clean energy and transport Simplified access, for all companies, universities, institutes in all EU countries and beyond. *The 7th research Framework Programme (FP7), innovation aspects of Competitiveness and Innovation Framework Programme (CIP), EU contribution to the European Institute of Innovation and Technology (EIT)

9 Three pillars of Horizon 2020: Societal Challenges Industrial Leadership Excellent Science

10 Horizon 2020

11 Priority 1 Societal challenges Concerns of citizens and society/eu policy objectives (climate, environment, energy, transport etc) cannot be achieved without innovation Breakthrough solutions come from multi-disciplinary collaborations, including social sciences & humanities Promising solutions need to be tested, demonstrated and scaled up Closer to market projects

12 Priority 2 Industrial leadership Strategic investments in key technologies (e.g. advanced manufacturing, micro-electronics) underpin innovation across existing and emerging sectors Europe needs to attract more private investment in research and innovation Europe needs more innovative SMEs to create growth and jobs Closer to market projects

13 Priority 3 Excellent science World class science is the foundation of tomorrow s technologies, jobs and wellbeing Europe needs to develop, attract and retain research talent Researchers need access to the best infrastructures

14 Suggested simplification Single set of simpler and more coherent participation rules. New balance between trust and control. Moving from several funding rates for different beneficiaries and activities to just two. Replacing the four methods to calculate overhead or "indirect costs with a single flat rate. Major simplification under the forthcoming financial regulation Some funding areas will have remote evaluation Successful applicants to get working more quickly: reduction of average time to grant (current average of around 350 days under FP7)

15 Potential broader access New SME Instrument! For SMEs within collaborative Work Programmes - dedicated SME projects to address societal challenges and enabling technologies For all regions tailored to support policy learning, twinning, networking, complementing Structural Funds For international partners broad access to Horizon 2020 ( mainstreaming ), strategic initiatives where there is mutual benefit For all forms of innovation - social innovation, services, pilots, stimulating demand through public procurement, standard setting

16 Summary Starts 1 January 2014 to end of 2020 Substantial monies available in excess of 70 billion Collaborative projects have less prescriptive in many cases New SME Instrument including potential single participation Funding available for closer to market projects Major simplification Shorter timescales to grant receipt planned in most cases Technology Readiness Levels (TRLs) used Grant payable in advance

17 GHA: Brief Overview Funding strategy development and call identification Project application development and submission Structuring project budgets to maximise opportunity Consortium partner search Liaison with EC institutions and decision makers in Brussels Contract negotiations with the EC Project Management Providing a personal, flexible approach, bespoke to client needs

18 GHB: Brief Overview Services include: Information and advice on EU policies and directives Monitoring of existing and proposed legislation Facilitating communication with MEPs, Commission Officials and decision makers Active lobbying in the European Parliament, European Commission and other relevant institutions Personal, flexible approach, bespoke to client needs

19 70 BILLION + * Horizon 2020 is now expected to receive 78.6bn in current prices over the next seven years and includes funding for nuclear research under the EURATOM. The final budget is an increase of nearly 30% in real terms compared with its predecessor, FP7.On this basis, the budget agreed for Horizon 2020 was 70.2bn. This baseline is adjusted for inflation (assumed to be 2% a year) over the lifetime of the programme to get to amounts in current prices. Current prices represent the real money that will be requested to the budget authority and finally distributed to beneficiaries through calls. *

20 Grahame Mansell-Grace Mobile : grahame@ghassociatesuk.com Website :